Xencor (NASDAQ:XNCR) Now Covered by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. assumed coverage on shares of Xencor (NASDAQ:XNCRGet Rating) in a report released on Wednesday, The Fly reports. The brokerage issued an overweight rating and a $37.00 price objective on the biopharmaceutical company’s stock.

Other research analysts also recently issued reports about the company. StockNews.com downgraded Xencor from a hold rating to a sell rating in a research report on Thursday, August 4th. Canaccord Genuity Group reaffirmed a buy rating and issued a $50.00 price target on shares of Xencor in a research report on Wednesday, July 6th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average target price of $49.71.

Xencor Stock Performance

Shares of XNCR stock opened at $26.95 on Wednesday. The stock’s 50 day simple moving average is $28.64 and its 200 day simple moving average is $26.90. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of 79.27 and a beta of 0.62. Xencor has a twelve month low of $19.35 and a twelve month high of $43.61.

Xencor (NASDAQ:XNCRGet Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.12). The business had revenue of $30.18 million during the quarter, compared to the consensus estimate of $34.35 million. Xencor had a return on equity of 3.15% and a net margin of 7.77%. On average, analysts forecast that Xencor will post -1.74 EPS for the current fiscal year.

Institutional Trading of Xencor

Several institutional investors have recently bought and sold shares of XNCR. US Bancorp DE boosted its stake in Xencor by 324.9% in the 2nd quarter. US Bancorp DE now owns 939 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 718 shares in the last quarter. Nisa Investment Advisors LLC acquired a new position in Xencor in the second quarter worth $27,000. Prospera Financial Services Inc acquired a new position in Xencor in the first quarter worth $28,000. Point72 Hong Kong Ltd acquired a new position in Xencor in the fourth quarter worth $41,000. Finally, Lazard Asset Management LLC boosted its stake in Xencor by 203.0% in the first quarter. Lazard Asset Management LLC now owns 4,485 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 3,005 shares in the last quarter. Institutional investors and hedge funds own 99.28% of the company’s stock.

Xencor Company Profile

(Get Rating)

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Read More

The Fly logo

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.